ScandiBio Therapeutics

info@scandibio.com
  • About Us
    • Our Science
    • Scientific rationale
    • The Team
  • Clinical Studies
    • Phase I/II: SERINE
    • Phase I: METABOLIC COFACTORS
    • Phase II: NAFLD
    • Phase II: AD/PD
    • Phase II: COVID-19
    • Phase III: COVID-19
  • Publications
  • News
  • Contact

Posts classified under: General

ScandiBio Therapeutics   →  General

Categories

  • News 12

Recent Posts

  • Phase 3 human clinical trial shows that metabolic activators accelerates recovery in COVID-19 patientsFebruary 24, 2021
  • Phase 2 human clinical trial shows that metabolic activators reduces liver fat in NAFLD patientsFebruary 4, 2021
  • Phase 2 human clinical trial shows that metabolic activators reduces recovery time in COVID-19 patients by nearly 30%October 6, 2020
  • A review article has been published discussing the current status of COVID-19 therapiesJuly 24, 2020
  • A review article has been published regarding the host-microbiome interactions in neurodegenerative diseasesJuly 8, 2020

Archives

  • February 2021
  • October 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
Copyright © 2020 ScandiBio Therapeutics. All rights reserved.